We are live on ! Find out more
GLRA

Gerald L. Ray & Associates Portfolio holdings

AUM $802M
1-Year Est. Return 21.01%
This Fund
S&P 500
This Quarter Est. Return
+6.68%
1 Year Est. Return
+21.01%
3 Year Est. Return
+38.23%
5 Year Est. Return
10 Year Est. Return
AUM
$730M
AUM Growth
+$40.7M
Cap. Flow
+$493K
Cap. Flow %
0.07%
Top 10 Hldgs %
28.63%
Holding
325
New
14
Increased
90
Reduced
109
Closed
10

Top Buys

Rank Stock Value
1
GGP
GGP Inc.
GGP
+$987K
2
ENB icon
Enbridge
ENB
+$766K
3
AMZN icon
Amazon
AMZN
+$641K
4
GILD icon
Gilead Sciences
GILD
+$524K
5
WDC icon
Western Digital
WDC
+$499K

Sector Composition

Rank Sector Weight
1 Healthcare 22.17%
2 Industrials 14.72%
3 Consumer Staples 10.5%
4 Financials 9.46%
5 Technology 9.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BA icon
26
Boeing
BA
$165B
$6.68M 0.92%
37,793
-439
-1% -$74.8K
MMP
27
DELISTED
Magellan Midstream Partners, L.P.
MMP
$6.46M 0.88%
84,042
-304
-0.4% -$23.6K
IBM icon
28
IBM
IBM
$202B
$6.4M 0.88%
38,419
+2,668
+7% +$447K
ACAD icon
29
Acadia Pharmaceuticals
ACAD
$4.25B
$6.31M 0.86%
183,650
+3,370
+2% +$119K
PFE icon
30
Pfizer
PFE
$140B
$5.94M 0.81%
183,139
-3,720
-2% -$117K
WMT icon
31
Walmart Inc
WMT
$871B
$5.8M 0.79%
241,479
-13,050
-5% -$300K
XOM icon
32
ExxonMobil
XOM
$651B
$5.6M 0.77%
68,280
-588
-0.9% -$49.1K
RTX icon
33
RTX Corp
RTX
$287B
$5.22M 0.71%
73,884
-1,478
-2% -$104K
MRK icon
34
Merck
MRK
$324B
$5.18M 0.71%
85,437
+613
+0.7% +$37.2K
GILD icon
35
Gilead Sciences
GILD
$161B
$5.1M 0.7%
75,025
+7,445
+11% +$524K
CSCO icon
36
Cisco
CSCO
$450B
$5.08M 0.7%
150,257
-1,700
-1% -$55.1K
EPD icon
37
Enterprise Products Partners
EPD
$83.8B
$5.07M 0.69%
183,627
+5,365
+3% +$150K
TMO icon
38
Thermo Fisher Scientific
TMO
$211B
$4.98M 0.68%
32,451
-1,097
-3% -$168K
HYG icon
39
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$16.3B
$4.63M 0.63%
52,723
+991
+2% +$86.6K
MO icon
40
Altria Group
MO
$122B
$4.5M 0.62%
63,037
EOG icon
41
EOG Resources
EOG
$78B
$4.47M 0.61%
45,845
-530
-1% -$52.9K
T icon
42
AT&T
T
$165B
$4.46M 0.61%
142,074
-662
-0.5% -$20.8K
CVX icon
43
Chevron
CVX
$388B
$4.31M 0.59%
40,098
+57
+0.1% +$6.39K
LOW icon
44
Lowe's Companies
LOW
$116B
$4.22M 0.58%
51,391
-20,900
-29% -$1.6M
IBB icon
45
iShares Biotechnology ETF
IBB
$9.31B
$4.21M 0.58%
43,083
+4,347
+11% +$416K
VRTX icon
46
Vertex Pharmaceuticals
VRTX
$121B
$4.09M 0.56%
37,370
-100
-0.3% -$8.8K
IYG icon
47
iShares US Financial Services ETF
IYG
$2.13B
$4.07M 0.56%
111,924
+2,655
+2% +$97.4K
FDX icon
48
FedEx
FDX
$74.5B
$3.95M 0.54%
20,239
+765
+4% +$146K
SPG icon
49
Simon Property Group
SPG
$74.5B
$3.92M 0.54%
22,760
-12
-0.1% -$2.14K
CBL
50
DELISTED
CBL& Associates Properties, Inc.
CBL
$3.87M 0.53%
405,401
+896
+0.2% +$9.19K

Similar funds

Gerald L. Ray & Associates's Q1 2017 Portfolio in Review

As of Q1 2017, Gerald L. Ray & Associates held 325 positions worth $730M, up 5.9% from $690M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Gerald L. Ray & Associates's Q1 2017 filing shows 14 new, 90 increased, 109 reduced and 10 closed positions. Its largest new stake was GGP Inc.: 40,367 shares worth $936K. The largest sale was Lowe's Companies, an estimated $1.6M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 22% a quarter earlier, followed by Industrials and Consumer Staples.

  • Gerald L. Ray & Associates's largest Q1 2017 buy was GGP Inc.: 40,367 shares worth $936K.
  • Gerald L. Ray & Associates added most to Amazon in Q1 2017, an estimated $641K increase.
  • Gerald L. Ray & Associates's biggest Q1 2017 reduction was Lowe's Companies, cutting an estimated $1.6M.
  • Gerald L. Ray & Associates fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $757K.
  • Gerald L. Ray & Associates's ten largest holdings make up 29% of its $730M portfolio in Q1 2017.
  • Gerald L. Ray & Associates opened 14 new positions and closed 10 in Q1 2017.
  • Gerald L. Ray & Associates's portfolio value rose 5.9% quarter-over-quarter to $730M.

Based on Gerald L. Ray & Associates's 13F filing for Q1 2017, filed 3 May 2017.